|
| Wednesday, 18 January 2017, 13:23 HKT/SGT | |
| |  | |
Source: Eisai | |
|
|
|
|
| Accelerating Access to Health Care in Low and Lower-Middle Income Countries |
TOKYO, Jan 18, 2017 - (JCN Newswire) - Eisai Co., Ltd. announced today that it is participating in Access Accelerated, a global partnership to advance access to non-communicable diseases (NCDs) prevention, treatment and care in low and lower-middle income countries.
Access Accelerated is the first multi-stakeholder, international initiative in the field of NCDs, consisting of 22 major pharmaceutical companies, including Eisai, in collaboration with the World Bank Group and the Union for International Cancer Control (UICC). The aim of Access Accelerated is to work towards the United Nation's Sustainable Development Goal target of reducing the number of premature deaths from NCDs in low and lower-middle income countries by one-third by 2030. In addition to the individual programs to improve access to health care run by each of the participating companies, this initiative will conduct pilots for improving prevention, treatment and care of NCDs in collaboration with the World Bank Group. Furthermore, in collaboration with the UICC, this initiative will support the provision of effective, sustainable diagnosis and treatment, for the purpose of improving cancer treatment and care.
To address global NCDs issues, Eisai has been running various initiatives in each country to improve access, including an Alzheimer's disease awareness and early detection campaign in China, and the introduction of tiered pricing, an affordable pricing model for our global product anticancer agent Halaven in seven Asian countries, including India, Thailand and the Philippines, where prices are set at several levels in accordance with the income levels of patients.
With regard to Eisai's participation in Access Accelerated, CEO Haruo Naito commented "One of the missions of the modern pharmaceutical industry is to make drugs accessible to all patients, no matter their socioeconomic status. In line with its human health care (hhc) philosophy, Eisai is pleased to take part in
initiatives like Access Accelerated to help address the social and medical needs of patients and their caregivers. For Eisai, pursuing solutions for global access challenges is both our responsibility and a long-term investment into the future."
About Access Accelerated
Access Accelerated is a first-of-its-kind, multi-stakeholder collaboration focused on improving NCDs care. Involving more than 20 pharmaceutical companies, the initiative works with partners such as World Bank Group and the Union for International Cancer Control (UICC) to help overcome a variety of access barriers to NCDs medicines in low-income and lower-middle income countries. Access Accelerated will support multi-stakeholder dialogue and begin on-the-ground work to improve NCDs prevention, diagnosis and treatment.
Contributing companies include: Almirall, Astellas, Bayer, Bristol-Myers Squibb, Celgene, Chugai, Daiichi Sankyo, Eisai, Eli Lilly and Company, EFPIA, GlaxoSmithKline, The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Johnson & Johnson, JPMA, Menarini, Merck KGaA, MSD, Novartis, Pfizer, PhRMA, Roche, Sanofi, Shionogi, Sumitomo Dainippon, Takeda and UCB. IFPMA will act as the Secretariat for Access Accelerated.
About Non-Communicable Diseases (NCDs)
NCDs, including cancers, cardiovascular diseases, chronic respiratory disease, diabetes and mental health disorders are the leading causes of death and disability worldwide. An estimated 80% of NCD-related deaths occur in low and lower-middle income countries, and countermeasures for NCDs have become an urgent issue.
About Eisai's initiatives for improving Access to Medicine
Eisai considers its activities for improving access to medicine in developing and emerging countries as a form of long-term investment for future growth, and is currently running various proactive, sustainable initiatives.
Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Topic: Press release summary
Source: Eisai
Sectors: Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| Eisai |
| Oct 30, 2025 13:43 HKT/SGT |
|
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma |
| Oct 28, 2025 23:30 HKT/SGT |
|
Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma |
| Oct 27, 2025 13:23 HKT/SGT |
|
Health Canada Grants Authorization for "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease |
| Oct 14, 2025 16:54 HKT/SGT |
|
LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" |
| Oct 8, 2025 11:03 HKT/SGT |
|
Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease |
| Oct 3, 2025 17:01 HKT/SGT |
|
Eisai Highlights Breadth of Oncology Research at ESMO 2025 |
| Sept 29, 2025 09:33 HKT/SGT |
|
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China |
| Sept 24, 2025 18:04 HKT/SGT |
|
LEQEMBI(R) (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia |
| Sept 17, 2025 17:20 HKT/SGT |
|
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation |
| Sept 12, 2025 12:20 HKT/SGT |
|
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month |
| More news >> |
 |
|
|
|
